Anti-Mitofusin-2 (N-Terminal) antibody produced in rabbit

Anti-Mitofusin 2 (N-terminal) antibody is suitable for immunoblotting (~86 kDa), immunoprecipitation, and immunofluorescence applications.
By immunoblotting, a working antibody concentration of 0.5-1 mg/mL is recommended using an extracts of rat and mouse brain mitochondria and a chemiluminescent detection reagent.
By indirect immunofluorescence, a working antibody concentration of 20-30 mg/mL is recommended using differentiated mouse C2 cells.
5-10 mg of the antibody immunoprecipitates mitofusin 2 from HeLa human epithelioid carcinoma cell lysate.

Anti-mitofusion 2 antibody may be used for immunoprecipitation in HeLa cells; immunoblotting in mouse and rat brain mitochondia and immunoflurescence in mouse C2 cells

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)

Anti-Mitofusin 2 (N-terminal) antibody recognizes human, rat, and mouse mitofusin 2. Detection of the mitofusin 2 band by immunoblotting is specifically inhibited with the immunizing peptide.

The antibody is specific for N-terminal of mitofusin 2 (~86 kDa)

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Mitofusins (Mfn1 and Mfn2) are the mammalian homologs of the Drosophila protein fuzzy onion (Fzo). They are transmembrane GTPases embedded in the outer membrane of mitochondria, essential for fusion of mitochondria in mammalian cells. Mfn1 and Mfn2 form homotypic and heterotypic complexes that are functional for fusion. Mitochondrial fusion is also important for cell growth, mitochondrial membrane potential, respiration, and embryonic development. Mice deficient in either Mfn1 or Mfn2 die in mid-gestation. Mfn2 mutant embryos have a specific and severe disruption of a layer of the placenta. Mitofusin 2 is broadly expressed, with highest expression in heart and skeletal muscle and is induced during myogenesis. Repression of Mfn2 causes morphological and functional fragmentation of the mitochondrial network into independent clusters and reduces mitochondrial membrane potential and glucose oxidation. Thus, Mfn2 is essential for the maintenance of mitochondrial network and controls mitochondrial metabolism. This Mfn2-dependent regulatory mechanism is disturbed in obesity by reduced Mfn2 expression. Mutations in Mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A, a neurological disorder that results from degeneration of axons in peripheral nerves.

synthetic peptide corresponding to amino acid residues 38-55 of human mitofusin 2 with C-terminal added cysteine, conjugated to KLH. The corresponding sequence differs by one amino acid in both rat and mouse mitofusin 2.

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.